-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VX2YLYJ1tALnsr6ZrZDnqcohP6gZjrkIaQgNfT+C+n6cBV0ImUDFx4AIFysDVQPs serPIpA5inpnyQZYnpq2Tg== 0000950142-02-000720.txt : 20020725 0000950142-02-000720.hdr.sgml : 20020725 20020725125924 ACCESSION NUMBER: 0000950142-02-000720 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020725 GROUP MEMBERS: CONCORD EFFEKTEN AG SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: EQUIDYNE CORP CENTRAL INDEX KEY: 0000352281 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 042608713 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-32922 FILM NUMBER: 02710691 BUSINESS ADDRESS: STREET 1: 13 COLUMBIA DR STE 5 CITY: AMHERST STATE: NH ZIP: 03031 BUSINESS PHONE: 6038806300 MAIL ADDRESS: STREET 1: 13 COLUMBIA DR STREET 2: STE 18 CITY: AMHERST STATE: NH ZIP: 03031 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN ELECTROMEDICS CORP DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CONCORD EFFEKTEN AG CENTRAL INDEX KEY: 0001174048 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: GROSS GALLUSSTRASSE 9 STREET 2: D-60311 CITY: FRANKFURT STATE: I8 ZIP: 00000 BUSINESS PHONE: 49069509518000 SC 13D/A 1 sc13da1-equidyne.txt AMENDMENT NO. 1 ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ----------------------- SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ----------------------- EQUIDYNE CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.10 PER SHARE (Title of Class of Securities) 29442R105 (CUSIP Number) DR. JOHANNES MAUSER MANAGING DIRECTOR CONCORD EFFEKTEN AG GROSSE GALLUSSTRASSE 9 D-60311 FRANKFURT, GERMANY TEL. NO.: (49) 69-509-51-8000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) ----------------------- JULY 25, 2002 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 1(f) or 1(g), check the following box [_]. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ================================================================================ - ----------------------------- ----------------------------- 29442R105 PAGE 2 OF 5 - ----------------------------- ----------------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Concord Effekten AG - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Germany - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 1,457,533 shares of Common Stock ------------------------------------------------ NUMBER OF 8 SHARED VOTING POWER SHARES BENEFICIALLY OWNED BY EACH -0- REPORTING ------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH 1,457,533 shares of Common Stock ------------------------------------------------ 10 SHARED DISPOSITIVE POWER -0- - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,457,533 shares of Common Stock - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.7% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON CO - -------------------------------------------------------------------------------- - ----------------------------- ----------------------------- 29442R105 PAGE 3 OF 5 - ----------------------------- ----------------------------- AMENDMENT NO. 1 TO SCHEDULE 13D This is Amendment No. 1 to the Schedule 13D filed by Concord Effeckten AG, a German company ("Concord"), with respect to the common stock, par value $0.10 per share (the "Common Stock"), of Equidyne Corporation, a Delaware corporation (the "Company"), which was originally filed on May 23, 2002. ITEM 1. SECURITY AND ISSUER. No material change. ITEM 2. IDENTITY AND BACKGROUND. No material change. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. No material change. ITEM 4. PURPOSE OF TRANSACTION. Item 4 is hereby amended and restated in its entirety as follows: Concord acquired the Common Stock described herein for investment purposes. In the first quarter of 2002, Concord was approached by two persons, each of whom Concord believed to be a representative of a significant stockholder group of the Company. Those persons asked whether Concord would be interested in having one of its representatives serve on the board of directors of the Company. Concord responded that it would be interested in assisting the Company through the provision of a director, but upon further consideration and analysis of the situation, Concord decided that it did not want to participate in a proxy contest involving the Company. Consequently, Concord informed those persons that it would decline to participate in their group. - ----------------------------- ----------------------------- 29442R105 PAGE 4 OF 5 - ----------------------------- ----------------------------- On July 25, 2002, Concord Corporate Finance GmbH, a subsidiary of Concord that provides financial advisory services, was engaged by Rosch AG Medizintechnik ("Rosch") to act as Rosch's financial advisor in connection with Rosch's interest in pursuing a business combination with the Company. Concord Corporate Finance GmbH has been informed that Rosch has sent letters to the Company indicating its interest in such a business combination, but that the current management of the Company has rebuffed these approaches and refused to meet with Rosch to discuss what Rosch believes are the compelling strategic reasons for such a business combination and the value that such a business combination could deliver to the Company's stockholders. Concord, through its subsidiary Concord Corporate Finance GmbH, is currently considering various possible courses of action in connection with this financial advisory engagement including, but not limited to, mergers, acquisitions, joint ventures and other extraordinary corporate transactions involving the Company. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. No material change. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO THE ISSUER. No material change. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Not Applicable. - ----------------------------- ----------------------------- 29442R105 PAGE 5 OF 5 - ----------------------------- ----------------------------- SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated as of July 25, 2002. CONCORD EFFEKTEN AG By: /s/ Thomas Stewens --------------------------------------- Name: Thomas Stewens Title: Managing Board By: /s/ Dr. Johannes Mauser --------------------------------------- Name: Dr. Johannes Mauser Title: Managing Director -----END PRIVACY-ENHANCED MESSAGE-----